IDH1 and cholangiocarcinoma: The ClarIDHy phase III multicenter trial randomized 185 patients with IDH1-mutated cholangiocarcinoma (91.4% ICC) that had progressed on standard chemotherapy to either ivosidenib or placebo [47].